Clinical stage development of Antigen Receptor Complex T-cells (ARC-T) that are readily silenced, activated and reprogrammed in vivo by administration of a tumo-targeting antigen protean called a sparX. The platform aims to achieve enhanced safety, improved efficacy, streamlined manufacturing and expanded utility. Backed by NEA, Novo, SR One, Takeda, Solasta, Quan, Clough, Mirae, JVC and LG.
US - South Atlantic
Phase l or ll, Pre-Clinical Stage
25 West Watkins Mill Road
Gaithersburg, MD 20878